Amber Khan, MD
Internal Medicine · Houston, TXNPI 1811108475
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Amgen at 28.6% of the total. Reporting peaked in 2019 at $781 and has fallen 95.7% since, to $34 in 2025.
Across 82 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$388
- Mallinckrodt Enterprises LLC$210
- Fresenius Kabi USA, LLC$161
- Novartis$97
- GSK$90
- UCB, Inc.$88
- plus $324 from 14 others
Across 642 payments — averaging $3169.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$487K
- Amgen$485K
- AbbVie$306K
- GSK$303K
- Sun Pharmaceutical Industries Inc.$284K
- E.r. Squibb & Sons, L.L.C.$80K
- plus $90K from 4 others
What the payments were for
- Food & beverage$1,358100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 27 | $388 |
| Mallinckrodt Enterprises LLC | 12 | $210 |
| Fresenius Kabi USA, LLC | 7 | $161 |
| Novartis | 6 | $97 |
| GSK | 5 | $90 |
| UCB, Inc. | 5 | $88 |
| Bristol Myers Squibb | 2 | $40 |
| Antares Pharma, Inc. | 3 | $35 |
| Lilly USA, LLC | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
| Pfizer | 2 | $29 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Johnson & Johnson | 2 | $27 |
| AbbVie | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Sanofi | 1 | $12 |
| Assertio Therapeutics, Inc. | 1 | $12 |
| Radius Health, Inc. | 1 | $11 |
How this compares
$1,358 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 50 | $584,645 |
| Leflunomide | 104 | $5,174 |
| Hydroxychloroquine Sulfate | 165 | $4,949 |
| Gabapentin | 200 | $2,861 |
| MethotrexateMethotrexate Sodium | 141 | $2,211 |
| Celecoxib | 94 | $2,142 |
| Duloxetine Hcl | 74 | $1,629 |
| Prednisone | 311 | $1,389 |
| Pregabalin | 12 | $1,369 |
| Diclofenac Sodium | 43 | $1,245 |
| Pilocarpine Hcl | 11 | $1,198 |
| Chlorzoxazone | 23 | $1,198 |
| Ibuprofen | 61 | $910 |
| Carisoprodol | 18 | $774 |
| Clobetasol Propionate | 18 | $706 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.